Remedium Lifecare, a leading pharmaceutical company, recently announced their fourth-quarter results for the fiscal year 2024. The results, declared on 27th May, 2024, revealed some significant changes in the company’s financial performance.
The total revenue for the quarter stood at ₹1408.49 Cr, showing a decline of 23.21% compared to the previous quarter. However, on a year-on-year basis, the revenue saw a staggering increase of 1763.59%. The company reported a net loss of ₹-53.72 Cr for Q4, marking a significant increase of 217.25% from the previous quarter.
Operating income took a hit, decreasing by 146.73% quarter-on-quarter and a massive 1004.48% year-on-year. The Diluted Normalized EPS for Q4 was reported at ₹-149.22, reflecting a substantial decrease of 25988.78% compared to the same period last year.
In terms of market performance, Remedium Lifecare delivered a negative return of -8.49% in the last week, -21.59% in the last six months, and -26.9% year-to-date. The company currently has a market capitalization of ₹738.86 Cr, with a 52-week high/low of ₹179.66 and ₹66.85 respectively.
Investors and analysts are closely monitoring the financials of Remedium Lifecare, given the fluctuations in revenue and profitability. The company’s performance in the upcoming quarters will be crucial in determining its future trajectory in the pharmaceutical industry. Stay tuned for more updates on Remedium Lifecare and its market performance.